WHAT IS CLAIMED IS:

1. Use of a selective JAK1 pathway inhibitor, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of chronic lung allograft dysfunction in a subject, wherein the selective JAK1 pathway inhibitor is {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharmaceutically acceptable salt thereof.

2. The use of claim 1, wherein the chronic lung allograft dysfunction is bronchiolitis obliterans syndrome.

3. The use of claim 1 or claim 2, wherein the subject is a lung transplant recipient.

4. The use of claim 1 or claim 2, wherein the subject is a double lung transplant recipient.

5. The use of claim 2, wherein the subject suffers from Grade 0p, Grade 1, Grade 2, or Grade 3 bronchiolitis obliterans syndrome as determined by International Society for Heart and Lung Transplantation (ISHLT) criteria.

6. The use of claim 1, wherein the selective JAK1 pathway inhibitor is {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile adipic acid salt.

7. Use of a selective JAK1 pathway inhibitor, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for reduction of the risk of bronchiolitis obliterans syndrome in a subject, wherein the selective JAK1 pathway inhibitor is {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharmaceutically acceptable salt thereof.

8. The use of claim 7, wherein the subject is a lung transplant recipient.

9. The use of claim 7, wherein the subject is a double lung transplant recipient.

10. The use of claim 7, wherein the selective JAK1 pathway inhibitor is {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile adipic acid salt.

11. Use of a selective JAK1 pathway inhibitor, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for reduction of the risk of lung re-transplantation in a subject, wherein the selective JAK1 pathway inhibitor is {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharmaceutically acceptable salt thereof.

12. Use of a selective JAK1 pathway inhibitor, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for reduction of the risk of hospitalization in a subject, wherein the medicament is formulated to be administered to said subject in an effective amount and wherein said subject is (a) diagnosed with bronchiolitis obliterans syndrome; (b) has had a lung transplantation within 1 to 5 years prior to the administration of the selective JAK1 pathway inhibitor, or a pharmaceutically acceptable salt thereof, and (c) does not have a decrease in FEV_1 attributable to a cause other than bronchiolitis obliterans syndrome, wherein the selective JAK1 pathway inhibitor is {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharmaceutically acceptable salt thereof.

13. Use of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1Hpyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of bronchiolitis obliterans syndrome in a subject.

14. The use of claim 13, wherein the pharmaceutically acceptable salt is {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile adipic acid salt.